Allurion Plans to Appeal NYSE Notice, Maintain NYSE Trading Amid Ongoing Compliance Efforts

Allurion Technologies has received notice from the NYSE to initiate delisting proceedings due to the company's failure to demonstrate compliance with listing requirements. Despite this, the company intends to appeal the decision and expects its shares to continue trading on the NYSE during the appeal process. Allurion plans to regain compliance through FDA approval, negotiations with creditors, and capital raising efforts. However, there is no guarantee that the company will regain compliance with NYSE listing requirements.